In vitro activities of LY163892, cefaclor, and cefuroxime
about
Molecular basis of the efficacy of cefaclor against Haemophilus influenzae.Effectiveness of short-course therapy (5 days) with cefuroxime axetil in treatment of secondary bacterial infections of acute bronchitisComparative in vitro activities of several new fluoroquinolones and beta-lactam antimicrobial agents against community isolates of Streptococcus pneumoniae.Influence of storage and susceptibility test conditions on stability and activity of LY163892 and four other cephalosporins.Pharmacokinetics of LY163892 in infants and children.Bactericidal titers of loracarbef (LY 163892) in serum and killing rates in volunteers receiving 400 versus 200 milligrams.Loracarbef versus cefaclor in the treatment of urinary tract infections in women.Development of revised quality control limits for disk diffusion susceptibility tests of selected cephem antibiotics with Haemophilus influenzae and description of a new control strain.Cefaclor: a contemporary look at susceptibility of key pathogens from around the globe.Loracarbef: a new orally administered carbacephem antibiotic.Uveitis attack and drug reaction due to cefuroxime axetil.Effect of loracarbef on the normal oropharyngeal and intestinal microflora.Loracarbef versus penicillin V in the treatment of streptococcal pharyngitis and tonsillitis.Comparison of loracarbef (LY163892) versus amoxicillin in the treatment of bronchopneumonia and lobar pneumonia.Bone and wound fluid concentrations of cephalosporins. Oral cefadroxil and parenteral cefuroxime compared in 52 patients with a trochanteric fracture.Prophylaxis with oral cefadroxil versus intravenous cefuroxime in trochanteric fracture surgery. A clinical multicentre study.Pharmacokinetics of loracarbef and interaction with acetylcysteine.In vitro activity and beta-lactamase stability of LY163892.Cathodic Stripping Voltammetric Determination of Cefaclor in Pharmaceutical Formulations
P2860
Q33746440-7B70D649-8972-4A7E-8B2A-BED12D38B5B2Q35120327-C25C707B-AECB-4081-86C5-0EBBE30FC493Q35250729-86284C65-187C-4900-B03B-42214D26C4EAQ35564276-E53F8B05-1859-4794-90B2-BFED1348202AQ35564813-C20FDC34-85F0-4ABA-957D-2FD826618C69Q35866980-28AD5FBD-A7FA-4AC3-AEDA-C0C76EC44676Q36753423-3B32BF39-5254-4126-A23C-219DB51CA7FFQ37125025-73937F93-D424-4EB0-8DA9-ADF76558DDFDQ38551015-8DD9B212-6691-44CA-8AFF-F0BC4B82335BQ40886376-7E44D4AE-0822-410A-AF3F-E0E4E4A8EE46Q41093645-549A0242-20EC-4D4F-8D33-8A682C8B78FDQ42150855-A87C283E-9424-4240-A367-5C7AFCAA1232Q44845011-4C04D91F-6DD5-4695-901E-97EBE8E08EBBQ46334574-71EEF7B8-B09B-45D5-9BDF-95ACED3408C5Q49238912-168B65F1-5CD3-45CD-BBBF-F7893910077DQ51038346-254D976C-9E85-4897-BBA1-D57DBF834C0BQ51604391-DBC0D220-5113-4C00-85F5-803FE70CAF8EQ54379306-1398F11A-3157-4528-89A6-542F3BC22354Q58250393-AE774AC0-A2CF-4036-BA08-651D02BB049D
P2860
In vitro activities of LY163892, cefaclor, and cefuroxime
description
1988 nî lūn-bûn
@nan
1988 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1988 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1988年の論文
@ja
1988年論文
@yue
1988年論文
@zh-hant
1988年論文
@zh-hk
1988年論文
@zh-mo
1988年論文
@zh-tw
1988年论文
@wuu
name
In vitro activities of LY163892, cefaclor, and cefuroxime
@ast
In vitro activities of LY163892, cefaclor, and cefuroxime
@en
type
label
In vitro activities of LY163892, cefaclor, and cefuroxime
@ast
In vitro activities of LY163892, cefaclor, and cefuroxime
@en
prefLabel
In vitro activities of LY163892, cefaclor, and cefuroxime
@ast
In vitro activities of LY163892, cefaclor, and cefuroxime
@en
P2860
P356
P1476
In vitro activities of LY163892, cefaclor, and cefuroxime
@en
P2093
Washington JA 2nd
P2860
P304
P356
10.1128/AAC.32.1.131
P407
P577
1988-01-01T00:00:00Z